Résumé
Introduction: Drug dealing among drug users has been associated with elevated risk-taking and negative health outcomes. However, little is known about the cessation of drug dealing among this population. Methods: We assessed time to cessation of drug dealing using Cox regression. We also used generalized estimating equation (GEE) analysis and chi-square analysis to examine factors associated with willingness to cease drug dealing. Results: In total, 868 participants reported drug dealing between November 2005 and March 2009. Among 381 participants dealing drugs at baseline, 194 (51%) ceased dealing. Incidence of dealing cessation was positively associated with spending less than $50 per day on drugs (Adjusted Hazard Ratio [AHR] = 1.88, 95% confidence interval [CI]: 1.14-3.10) and negatively associated with buying drugs from the same source (AHR = 0.60, 95% CI: 0.37-0.98). In a GEE analysis, willingness to cease dealing was positively associated with older age (Adjusted Odds Ratio [AOR] = 1.02, 95% CI: 1.01-1.03), crack use (AOR = 2.00, 95% CI: 1.44-2.79), public injecting (AOR = 1.95, 95% CI: 1.55-2.43), and reporting that police presence affects drug purchases (AOR = 1.53, 95% CI: 1.22-1.91), and negatively associated with crystal methamphetamine injection (AOR = 0.62, 95% CI: 0.47-0.83). Discussion: Intensity of drug use and acquisition method were predictive of dealing cessation. Willingness to cease dealing was associated with a range of risky drug-related activities. Interventions to reduce drug dealing should be conceived in tandem with addiction treatment strategies.
Langue d'origine | English |
---|---|
Pages (de-à) | 459-463 |
Nombre de pages | 5 |
Journal | Drug and Alcohol Dependence |
Volume | 118 |
Numéro de publication | 2-3 |
DOI | |
Statut de publication | Published - nov. 1 2011 |
Publié à l'externe | Oui |
Note bibliographique
Funding Information:Dan Werb, Martin Bouchard, Thomas Kerr, Jiezhi Qi, Jean Shoveller, and Evan Wood have no conflicts of interest to declare. Julio Montaner has received grants from, served as an ad hoc adviser to, or spoken at events sponsored by Abbott, Argos Therapeutics, Bioject Inc., Boehringer Ingelheim, BMS, Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Janssen-Ortho, Merck Frosst, Panacos, Pfizer Ltd., Schering, Serono Inc., TheraTechnologies, Tibotec (J&J), and Trimeris.
Funding Information:
The study was supported by the US National Institutes of Health (R01DA011591, R01DA028532 and R01DA021525) and the Canadian Institutes of Health Research (MOP-79297, RAA-79918 and RAA-79918). Dan Werb and Thomas Kerr are supported by the Michael Smith Foundation for Health Research and the Canadian Institutes of Health Research. The funders had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.
ASJC Scopus Subject Areas
- Toxicology
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't